Hum. Reprod. Advance Access originally published online on June 2, 2005
Human Reproduction 2005 20(8):2052-2060; doi:10.1093/humrep/dei043
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MINI REVIEW: DEVELOPMENTS IN REPRODUCTIVE MEDICINE |
Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review
1 Institut für Pathologie, Charité, Humboldt-Universität Berlin, Schumannstr. 20–21, D-10117 Berlin, 2 EPES Epidemiology, Pharmacoepidemiology and Systems Research GmbH, Wulffstr. 8, D-12165 Berlin, Germany and 3 Department of Public Health, University of Capetown, Capetown, South Africa and Mailman School of Public Health, New York, NY, USA
4 To whom correspondence should be addressed. Email: manfred.dietel{at}charite.de
Hormone replacement therapy (HRT) has gained widespread and in some areas indiscriminate use. In reference to recent epidemiological studies which showed unexpected and controversial associations of HRT use with malignant tumours, here we review the current understanding of the dynamics of tumour growth. The pathomorphological characteristics and sex hormone sensitivity of cancers of the breast, endometrium, ovary and colon are discussed. The development of cancer from the first malignant tumour cell to clinical diagnosis takes many years. Hormones can influence tumour growth, but it is questionable whether hormones induce malignant tumours de novo. It is much more likely that hormones ‘merely’ promote the growth of already existing tumour cells. The long developmental process of tumours is in apparent contradiction to results of some epidemiological studies that describe an increased cancer risk, implying primary initiation, in HRT users within observation periods of 1–6 years. The mechanisms of initiation versus promotion of hormone-sensitive cancers, particularly breast cancer, are only partly understood. The conventional methods of epidemiological studies cannot detect potential risk factors without bias if they do not include a pathomorphological component on growth characteristics. The results of previous studies should be interpreted with great caution with regard to tumour biology.
Key words: cancer/endometrium/epidemiology/hormone receptors/pathomorphology
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Krieger Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections Int. J. Epidemiol., June 1, 2008; 37(3): 627 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Robbins and C. A. Clarke Regional Changes in Hormone Therapy Use and Breast Cancer Incidence in California From 2001 to 2004 J. Clin. Oncol., August 10, 2007; 25(23): 3437 - 3439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Kumar, E. Cureton, V. Shim, T. Sakata, D. H. Moore, C. C. Benz, L. J. Esserman, and E. S. Hwang Type and Duration of Exogenous Hormone Use A3ects Breast Cancer Histology Ann. Surg. Oncol., February 1, 2007; 14(2): 695 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Clarke, S. L. Glaser, C. S. Uratsu, J. V. Selby, L. H. Kushi, and L. J. Herrinton Recent Declines in Hormone Therapy Utilization and Breast Cancer Incidence: Clinical and Population-Based Evidence J. Clin. Oncol., November 20, 2006; 24(33): e49 - e50. [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Bond, K. M. Hirshfield, T. Kirchhoff, G. Alexe, E. E. Bond, H. Robins, F. Bartel, H. Taubert, P. Wuerl, W. Hait, et al. MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner. Cancer Res., May 15, 2006; 66(10): 5104 - 5110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sitruk-Ware New progestagens for contraceptive use Hum. Reprod. Update, March 1, 2006; 12(2): 169 - 178. [Abstract] [Full Text] [PDF]
|
|